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Summary Recent epidemiological studies have demonstrated that nearly half of all patients
with heart failure (HF) have preserved left ventricular ejection fraction (HFPEF). Compared
to those with reduced EF, patients with HFPEF are older, more likely to be women, less likely
to have coronary artery disease, and more likely to have hypertension and atrial ﬁbrillation.
Patients with HFPEF receive different pharmacological as well as nonpharmacological treat-
ments from those with reduced EF. Morbidity and mortality in patients with HFPEF are largely
similar to those with reduced EF. Although much information has recently been obtained about
the clinical characteristics, medications, and outcomes of HFPEF by large-scale clinical and
epidemiological studies, effective management strategies need to be established for this type
of HF.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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binary division between ‘‘preserved’’ and ‘‘reduced’’ EF.References ................................................
ntroduction
substantial portion of patients with symptomatic heart
ailure (HF) has been reported to have relatively normal
r preserved left ventricular (LV) ejection fraction (EF) [1].
‘HF with preserved EF (HFPEF)’’ has been deﬁned as the
resence of typical HF symptoms and signs with an EF of
ore than 40% or 50%.
Prior studies demonstrated that patients with HFPEF are
lder, more often female, and have hypertension compared
o those with reduced EF [1—4]. Recently, large-scale reg-
stry databases such as EuroHeart Failure Survey, Acute
ecompensated Heart Failure National Registry (ADHERE),
nd OPTIMIZE-HF (Organized Program to Initiate Lifesav-
ng Treatment in Hospitalized Patients With Heart Failure)
emonstrated that patients with preserved and reduced EF
ad similar prognosis [5—7]. Even though these registries
tudied the outcomes in a large and broad sample of HF
atients, their duration of follow-up is short and very little
nformation is currently available based on the long-term
ollow-up over 1 year.
Moreover, most previous studies have been conducted
ainly in the USA and Europe and very limited informa-
ion is available in Japan. Our previous studies in Fukuoka
ere the ﬁrst detailed analysis of clinical characteristics,
anagement, and outcomes including mortality and HF-
elated readmission in HF patients encountered in routine
linical practice [3,8,9]. Even though our previous studies
igure 1 Histogram of left ventricular ejection fraction (LVEF) am
uced with permission from Tsuchihashi-Makaya et al. [11]).
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ave provided a valuable insight into the characteristics of
F patients in Japan, the generalization of these results is
uestioned because it was conducted in a small number
f patients (n = 230). Therefore, it is of critical impor-
ance to analyze the data of HF patients on a national
asis.
The aim of the present review is to describe the clinical
haracteristics and outcomes of patients with HFPEF based
n the previous cohort studies including the Japanese Car-
iac Registry of Heart Failure in Cardiology (JCARE-CARD),
national prospective registry database of patients hos-
italized due to the worsening of HF symptoms in Japan
10,11].
FPEF and diastolic HF
F has been traditionally classiﬁed as ‘‘diastolic’’ or
‘systolic’’, but this nomenclature has become the subject
f controversy [12,13]. In this review, we use the term of
‘HFPEF’’ rather than ‘‘diastolic HF’’ because this termi-
ology has been adopted in the guidelines of the American
ollege of Cardiology/American Heart Association [14] and
he European Society of Cardiology [15]. There is no simpleong patients hospitalized with heart failure (n = 1692) (repro-
nstead there might be a ‘‘border zone’’ where there is
ncertainty. In addition, the assessment of EF varied from
ualitative to quantitative measurement of EF, fractional
hortening, or a wall motion score. The diagnostic criteria
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of HF also varied from clinical examination by a single
investigator to the use of epidemiological criteria such as
in the Framingham study.
Large-scale registry of HF in Japan
Patients registered in the JCARE-CARD displayed a wide dis-
tribution of EF values (Fig. 1) [11]. A total of 429 patients
(26%) had EF ≥50% and were classiﬁed as having ‘‘HFPEF’’
and 985 patients (58%) had EF <40% (HF with reduced EF).
The remaining 278 patients (16%) had EF between 40%
and 50%. As expected, the mean EF was 27.0% in patients
with reduced EF (n = 985) whereas it was in the normal
range for patients with PEF (62.4%, n = 429). Compared with
i
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s
(
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Table 1 Baseline characteristics of heart failure patients with re
Characteristic Total cohort (n = 1692)
LVEF 38.8± 16.8
Demographics
Age (years) 71.0± 13.3
Older than 65 years (%) 69.3
Male (%) 59.7
Causes of heart failure (%)
Ischemic 32.0
Hypertensive 24.6
Cardiomyopathic, dilated 24.0
Cardiomyopathic, hypertrophic 2.2
Undetermined 15.7
History
Hypertension (%) 52.6
Diabetes mellitus (%) 29.8
Hyperlipidemia (%) 24.6
Chronic renal failure (%) 11.7
Serum creatinine (mg/dL) 1.38
Anemia (%) 20.7
Hemoglobin (g/dL) 12.3
Stroke (%) 14.7
COPD (%) 6.5
Atrial ﬁbrillation (%) 35.0
Sustained VT/VF (%) 6.1
Prior PCI (%) 17.4
Prior CABG (%) 9.2
NYHA class at discharge (%)
I 34.9
II 54.5
III 5.9
IV 3.5
Vital signs at discharge
Body mass index (kg/m2) 22.7± 4.2
Heart rate (bpm) 70.5± 12.0
Systolic blood pressure (mmHg) 117.0± 18.6
Diastolic blood pressure (mmHg) 66.1± 11.6
Plasma BNP at discharge (pg/dL) 390± 508
LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulm
lation; PCI, percutaneous coronary intervention; CABG, coronary artery
natriuretic peptide (reproduced with permission from Tsuchihashi-Maka15
atients with reduced EF, the patients with PEF were sig-
iﬁcantly older and were more often women. The causes
f HF were ischemic heart disease and dilated cardiomy-
pathy in a higher percentage of patients with reduced EF,
hereas hypertensive heart disease and hypertrophic car-
iomyopathy were more common in HFPEF. Patients with
FPEF were also more likely to have a history of hyper-
ension, renal failure, anemia, and atrial ﬁbrillation. In
ontrast, hyperlipidemia, sustained ventricular tachycardia
r ventricular ﬁbrillation, and prior coronary revascular-
zation were more common in patients with reduced EF
Table 1). ACE inhibitors, -blockers, spironolactone, and
tatins were more prescribed in patients with reduced EF
Table 2). In contrast, more patients with HFPEF had calcium
hannel blockers.
duced ejection fraction (EF) vs. preserved EF.
Reduced EF (n = 985) Preserved EF (n = 429) p-Value
27.0± 7.4 62.4± 9.4 <0.001
66.6± 13.8 73.6± 12.6 <0.001
60.5 81.1 <0.001
72.2 52.7 <0.001
39.8 25.4 <0.001
21.6 44.3 <0.001
36.3 5.1 <0.001
0.4 9.6 <0.001
13.7 26.8 <0.001
50.4 68.3 <0.001
33.3 29.4 0.150
28.8 22.8 0.020
10.4 14.9 0.015
1.36 1.40 0.712
13.2 27.1 <0.001
12.8 11.6 <0.001
14.6 15.0 0.844
6.1 8.6 0.089
24.5 38.3 <0.001
9.6 5.0 0.004
20.8 15.2 0.014
11.4 7.8 0.040
35.7 37.3 0.428
55.7 53.6
5.9 5.0
2.7 4.1
22.7± 4.2 22.8± 4.4 0.658
70.9± 12.4 69.4± 12.5 0.041
113.2± 17.4 121.9± 20.2 <0.001
66.0± 11.8 66.8± 11.9 0.243
396± 551 366± 386 0.415
onary disease; VT/VF, ventricular tachycardia/ventricular ﬁbril-
bypass grafting; NYHA, New York Heart Association; BNP, B-type
ya et al. [11]).
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Table 2 Discharge medications of heart failure patients with reduced ejection fraction (EF) vs. preserved EF.
Total cohort (n = 1613) Reduced EF (n = 947) Preserved EF (n = 401) p-Value
ACE inhibitors 38.7 44.2 25.4 <0.001
ARBs 46.4 45.9 48.9 0.322
ACE inhibitors or ARBs 79.1 83.5 70.1 <0.001
ACE inhibitors and ARBs 6.0 6.7 4.2 0.086
Beta-blocker 57.5 65.9 40.1 <0.001
Diuretic 87.0 88.1 84.8 0.101
Spironolactone 42.2 45.9 36.4 <0.001
Digitalis 27.2 28.7 24.2 0.088
Calcium channel blocker 25.4 17.1 42.9 <0.001
Nitrates 23.0 22.6 20.2 0.330
Antiarrhythmic 18.5 20.9 17.2 0.119
Aspirin 48.4 49.2 43.9 0.074
Warfarin 39.8 42.9 37.7 0.075
Statin 21.0 23.1 15.0 <0.001
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker (reproduced with permission from Tsuchihashi-Makaya et al.
[11]).
Figure 2 Adjusted event-free curves from (A) all-cause death, (B) cardiac death, (C) rehospitalization due to heart failure (HF),
and (D) all-cause death or rehospitalization due to HF in patients with reduced ejection fraction (EF) (straight lines; n = 847) com-
pared with preserved EF (dashed lines; n = 370). The data were adjusted for differences in baseline variables, including age, gender,
ischemic heart disease, dilated cardiomyopathy, hypertension, hyperlipidemia, renal failure, anemia, sustained ventricular tachy-
cardia or ﬁbrillation, atrial ﬁbrillation or ﬂutter, prior percutaneous coronary intervention, prior coronary artery bypass grafting,
heart rate, systolic blood pressure, discharge medications such as angiotensin-converting enzyme inhibitors, -blockers, calcium
channel blockers, and statin (reproduced with permission from Tsuchihashi-Makaya et al. [11]).
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During the follow-up period of 2.4 years, 235 (19.3%)
atients died; 150 (12.3%) from cardiac causes and 85 (7.0%)
rom non-cardiac causes. The rates of all-cause mortality
ithin 1 year after discharge were 8.9% and 11.6% in patients
ith reduced and preserved EF, respectively, which did not
iffer between groups (p = 0.13). The prevalence of car-
iac mortality within all-cause mortality was 66% and 59%
n patients with reduced EF and preserved EF, respectively,
hich did not differ between groups (p = 0.27). Rehospital-
zation rates during the same period were 23.7% and 25.7%
n reduced and preserved EF, respectively, which also did not
iffer between groups (p = 0.47). The rates of all-cause mor-
ality and rehospitalization within 1 year after discharge in
atients with EF between 40% and 50% were 7.0% and 24.8%,
espectively, which did not differ from those in the other two
roups.
There was no signiﬁcant difference in survival curves
ree from all-cause death between patients with reduced
nd preserved EF [adjusted hazard ratio (HR) 0.930 and
5% conﬁdence interval (CI) 0.664—1.303; p = 0.675]. There
ere also no signiﬁcant differences in cardiac death
etween groups (adjusted HR 0.862; 95%CI 0.563—1.321;
= 0.495). The combined all-cause death or rehospitaliza-
ion free curves did not differ between groups (adjusted
R 1.082 and 95%CI 0.858—1.365; p = 0.507) (Fig. 2 and
able 3).
The results of subgroup analysis for all-cause mortality
tratiﬁed by age (≥65 years vs. <65 years), gender (male
s. female), etiology (ischemic vs. non-ischemic), presence
f hypertension, presence of diabetes, and medication use
t discharge demonstrated that the association between EF
nd all-cause death in each subgroup was similar to that
ound on the primary analysis (Table 4).
revalence
he prevalence of HFPEF ranged from 24% to 55% based on
revious studies (Table 5) [4,16—30]. Even though the def-
nitions for PEF have varied and the appropriate EF cutoff
alues have not been established, the previous ﬁndings were
ostly consistent. The Euro Heart Failure Survey reported
hat 3148 out of 6806 patients (46.3%) had HF and preserved
ystolic function [5]. In the OPTIMIZE-HF registry, includ-
ng 48,612 patients hospitalized for HF, 41,267 (84.9%) had
ata for EF or a qualitative LV function assessment and,
f the patients with LV function assessed, 21,149 (51.2%)
ad EF ≥40% or a qualitatively normal/mildly impaired EF
7].
linical characteristics
atients with HFPEF are older, more often female, and more
ikely to have hypertension (Tables 2 and 6). Higher preva-
ence of HFPEF in elderly patients most likely reﬂects the
ffects of aging on myocardial structure [31].
Myocardial infarction or coronary artery disease is less
ommon in HFPEF. Other atherosclerotic diseases such as
eripheral arterial disease and stroke are also less com-
on. Conversely, hypertension and hypertensive etiology
re more common in HFPEF. Left ventricular hypertrophy
s also more common.
18 H. Tsutsui et al.
Table 4 Subgroup analysis of all-cause death for heart failure patients with reduced ejection fraction (EF) vs. preserved EF.
Subgroup N HR Reduced EF vs. Preserved EF 95% CI
Age
≥65 yr 804 0.949 0.655—1.375
<65 yr 413 1.253 0.540—2.909
Gender
Male 806 0.878 0.576—1.339
Female 411 0.995 0.548—1.806
Etiology
Ischemic 425 0.919 0.540—1.564
Non-ischemic 792 0.946 0.602—1.487
Hypertension
Hypertension 677 0.949 0.583—1.544
No hypertension 534 1.007 0.612—1.657
Diabetes
Diabetes 385 0.607 0.321—1.147
No diabetes 831 1.057 0.704—1.588
Medication use at discharge
ACE inhibitor/ARB 970 0.879 0.555—1.390
No ACE inhibitor/ARB 247 1.011 0.598—1.709
-blocker 708 0.914 0.543—1.540
No -blocker 509 0.957 0.606—1.512
Spironolactone 686 1.257 0.678—2.234
No spironolactone 531 0.835 0.550—1.268
HR, hazard ratio; CI, conﬁdence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. Heart failure with
eserv
ﬁ
p
c
p
v
H
i
w
c
E
i
a
H
i
t
A
h
s
d
r
t
s
u
t
d
a
H
i
e
d
f
a
a
H
p
s
T
f
i
d
a
M
P
areduced EF was used as a reference against heart failure with pr
permission from Tsuchihashi-Makaya et al. [11]).
Patients with HFPEF also have higher prevalence of atrial
brillation, which might be a consequence as well as a
recipitating factor for clinical deterioration of HF. It may
ause hemodynamic deterioration and worsen HF by multi-
le mechanisms including loss of atrial contraction, rapid
entricular rate, and often short ventricular ﬁlling time.
owever, the prognostic impact of atrial ﬁbrillation in HF
s a controversial issue. In JCARE-CARD, atrial ﬁbrillation
as not an independent risk for long-term adverse out-
omes including death or rehospitalization irrespective of
F [32].
Anemia is also common especially in HFPEF occurring
n 20—30% of patients. In parallel to higher prevalence of
nemia in HFPEF, hemoglobin level is lower in this group.
igher prevalence of anemia in HFPEF is also documented
n patients enrolled in large-scale clinical trials [33]. In
he sub-analysis of CHARM (Candesartan in Heart Failure:
ssessment of Reduction in Mortality and Morbidity), lower
emoglobin was associated with greater EF [33]. The authors
peculated that anemia was associated with greater EF
ue to increased cardiac output, reduced systemic vascular
esistance, and the resultant reduction in the afterload to
he heart [34,35]. Although the precise mechanisms respon-
ible for the association between anemia and HFPEF are
nclear, it may be a unique clinical feature associated with
his type of HF. Most studies including JCARE-CARD have
emonstrated higher mortality rates in HF patients with
nemia [36].
a
t
m
m
wed EF when the hazard ratios were calculated (reproduced with
Diabetes mellitus is also common in both types of HF:
FPEF and HF with reduced EF. However, this comorbidity
s not more frequent in HFPEF, despite the experimental
vidence that diabetes may be a risk factor for diastolic
ysfunction [37—39].
There is no clear difference in the prevalence of renal
ailure or serum creatinine concentration between HFPEF
nd reduced EF. This may be unexpected, given the older
ge of patients and higher prevalence of hypertension with
FPEF. In fact, chronic renal failure was more prevalent in
atients with HFPEF whereas serum creatinine levels were
imilar between reduced EF and HFPEF in JCARE-CARD [40].
his may be due to the fact that renal blood ﬂow and renal
unction are also depressed in HF with reduced EF. More
mportantly, decreased renal function has been consistently
emonstrated to be an independent risk factor for morbidity
nd mortality in HF patients irrespective of EF [40].
edical treatment
atients with PEF were less likely to receive ACE inhibitors
nd -blockers (Tables 2 and 6). These results may reﬂect
lack of evidence-based strategies for effective medica-
ion for HFPEF. In contrast, calcium channel blocker use is
uch greater in HFPEF, reﬂecting the view that these agents
ay be of beneﬁt especially complicated with hypertension
hereas they are harmful in HF with reduced EF.
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Table 5 Prevalence of heart failure with preserved ejection fraction (HFPEF).
Study or author/region
or country
Reference Year Number of
patients
EF cutoff values for
HFPEF
HFPEF/total
(%)
Japan
Single center
Ito/Osaka 16 1978—1985 298 ≥41% 40
Multicenter
Tsutsui/Fukuoka 3 1997 230 ≥50% 35
CHART/Tohoku 17 2000 1,154 ≥50% 30
Kawashiro/Tokyo 18 2001—2002 2,808 >50% 34
Ogawa/Iwate 19 2002—2005 391 ≥50% 34
JCARE-CARD/Japan 11 2003—2004 1,414 ≥50% 26
Other countries
Single center
Malki/USA 20 — 187 ≥50% 30
Varela-Roman/Spain 21 1991—1994 229 ≥50% 29
Thomas/USA 22 — 225 ≥45% 46
Smith/USA 23 1996—1998 413 ≥40% 48
Varadarajan/USA 24 1990—1999 2,258 ≥55% 43
Owan/USA 25 1987—2001 4,596 ≥50% 47
Multicenter
Philbin/USA 2 1995—1997 1,291 ≥50% 24
Gustafsson/Denmark 26 1993—1996 5,491 Wall motion
index>1.6 (LVEF>48%)
42
Cohen-Solal/France 27 1997 739 >40% 46
Euro Heart Survey/EU 5 2000—2001 5,451 ≥40% 46
Sacha Bhatia/Canada 28 1999—2001 2,802 ≥50% 31
OPTIMIZE 7 2007 48,612 >40% 51
Medicare
Dauterman/USA 29 1993—1996 782 ≥40% 54
a
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l
Ahmed/USA 30 1994
Masoudi/USA 31 1998—1999
(—) Not reported.
Outcomes
Previous studies reported more favorable survival in patients
with PEF [24]. However, its difference is quite small. In con-
trast, Bhatia et al. reported that the post-discharge survival
of patients with HFPEF was similar to those with reduced EF
[27]. The OPTIMIZE-HF also demonstrated that patients with
PEF had similar mortality risk (9.5% vs. 9.8%; p = 0.459) and
rehospitalization rates compared to those with reduced EF
[7]. JCARE-CARD also showed that the post-discharge long-
term survival and rehospitalization due to the worsening of
HF were similar between preserved and reduced EF [11].
Remaining questions
Many questions remain about the clinical characteristics of
HFPEF. First, why is HFPEF more common in women than
men? Second, what is the role of atrial ﬁbrillation? Is atrial
ﬁbrillation a cause of HF or does it only precipitate HF
because of underlying diastolic dysfunction? The interaction
between HFPEF and atrial ﬁbrillation is further confounded
by the evidence that diastolic dysfunction itself can be
d
p
h
s
t438 >40% 55
19,710 ≥50% 35
predictor of future atrial ﬁbrillation. Third, the great-
st remaining question is how to treat and manage HFPEF.
espite the risk for long-term adverse outcomes, sufﬁcient
ata are lacking to prove the effective treatment strategies
or HFPEF. Current HF guideline recommendations include
ontrol of blood pressure in hypertension, ventricular rate
ontrol in atrial ﬁbrillation, and use of diuretics to control
ulmonary congestion and peripheral edema for patients
ith PEF [14,15]. The CHARM-Preserved study observed a
eduction in HF hospitalizations for HF patients and PEF who
ere treated with the ARB candesartan in addition to stan-
ard background therapy [41]. On the contrary, the recent
linical trial I-PRESERVE (Irbesartan in Patients with Heart
ailure and Preserved Ejection Fraction) could not conﬁrm
he clinical beneﬁts of the ARB irbesartan in HF with PEF
42]. In the JCARE-CARD study, HF patients with PEF were
ess likely to be treated with an ACE inhibitor or ARB and
-blockers than those with reduced EF. Despite the lack of
ata to support the efﬁcacy of these drugs, they may be
otentially beneﬁcial in patients with HF and PEF who also
ave other indications for these agents, such as hyperten-
ion, diabetes mellitus, or coronary artery disease. Given
he high post-discharge clinical event rate and the lack of
20
H
.
Tsutsuiet
al.
Table 6 Comparison of clinical characteristics and medications between heart failure with preserved ejection fraction and reduced ejection fraction.
Japan Other countries
Author/study name Tsutsui
et al.
CHART JCARE-CARD Varela-Roman
et al.
Thomas
et al.
Owan et al. Philbin et al. Euro Heart
Survey
Bhatia et al. Ahmed
et al.
Masoudi et al.
Reference [3] [17] [11] [21] [22] [24] [2] [5] [27] [29] [30]
Year 1997 2000 2003—2004 1991—1994 — 1987—2001 1995—1997 2000—2001 1999—2001 1994 1998—1999
Mean age (year) 69/68 70/65 74/67 67/66 59/54 74/72 75/74 71/67 75/72 — 80/78
Women (%) 51/33 44/42 47/28 64/33 56/35 56/35 70/50 55/29 66/37 69/49 79/49
Myocardial
infarction (%)
34/36 — 18/35 — — — — — 17/39 — 21/38
Coronary artery
disease (%)
— 18/36 — — 22/30 53/64 23/35 59/69 36/49 20/24 46/65
Hypertension (%) 66/44 57/38 68/50 53/52 78/74 63/48 49/43 59/50 55/49 19/15 69/61
LV hypertrophy (%) 51/25 — 31/31 49/36 22/42 — — — — — —
Atrial ﬁbrillation
(%)
30/32 39/30 38/25 45/34 19/10 41/29 29/24 25/23 32/24 — 36/30
Stroke (%) — — 15/15 — — — — 16/14 15/15 — 17/18
Diabetes mellitus
(%)
30/31 23/22 29/33 17/24 40/34 33/34 33/36 26/28 32/39 25/26 37/40
Renal failure (%) 11/14 — 15/10 — 15/9 — — 5/6 — — 36/47
Diuretics (%) 61/75 73/79 85/88 76/79 93/95 — 59/64 85/87 — 30/27 —
ACE inhibitor (%) 43/68 72/77 25/44 12/45 62/85 — 29/48 58/78 — 31/39 —
ARB (%) — 49/46 — — — — 4/6 — — —
-Blocker (%) 18/26 26/37 40/66 8/6 18/10 — 23/17 39/46 — — —
Digitalis (%) 39/52 44/43 24/29 71/56 27/57 — 30/44 31/41 — 47/51 —
Calcium antagonist
(%)
51/30 — 43/17 18/12 34/14 — 39/24 28/16 — — —
LV, left ventricular; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
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proven medical therapies for HFPEF, there is a clear need to
establish effective management strategies.
Conclusions
HFPEF is common and accounts for a signiﬁcant proportion of
patients with HF. They have similar morbidity and mortality
to those with reduced EF. Therefore, HFPEF does not read-
ily mean ‘‘good’’ prognosis. Given the high risk of adverse
clinical events and the lack of a sufﬁcient evidence to guide
the treatment, effective management strategies need to be
established for HFPEF.
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